Sold as R-Gene 10. Every FDA application for this active ingredient.
As of Nov 15, 2026, FDA lists 1 application for Arginine Hydrochloride (sold as R-Gene 10), first approved Feb 28, 1973, with 0 new uses approved and 0 published complete response letters.
| Effectiveness and Safety of Cellbooster Hair in Healthy SubjectsHair and Scalp Health · Suisselle | Not applicable | Not yet recruiting | Nov 10, 2026 |
| Arginine-Restricted Diet Combined With Chemoradiotherapy in Neoadjuvant Rectal Cancer: A Phase Ib/II TrialRectal Cancer Patients · Xuelei Ma MD | Phase 1 / Phase 2 | Not yet recruiting | Nov 3, 2026 |
| Gut-Liver-Muscle Axis in Cancer CachexiaHead & Neck Cancer · University of Colorado, Denver | Not applicable | Not yet recruiting | Nov 2, 2026 |
| NON-SURGİCAL PERİODONTAL THERAPY WİTH L-ARGİNİNEPeriodontal Disease, Periodontal Diseases · Alanya Alaaddin Keykubat University | Not applicable | Active, not recruiting | Oct 23, 2026 |
| The Effects of Increased Water Intake on Muscle Function, Physical Performance, and Endocrine Regulation in Low-Drinking Older AdultsDehydrated, Water-Electrolyte Imbalance, Malnutrition, Dehydration (Physiology) · Polytechnic University of Santarém | Not applicable | Recruiting | Oct 23, 2026 |
| Immunonutrition for Surgical Prehabilitation of Patients With Upper GI CancerUpper GI Cancer · Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal | Not applicable | Enrolling by invitation | Oct 20, 2026 |
| Targeted Nutritional Intervention (HMB, Arginine, Glutamine) in Patients With Pancreatic CancerPDAC, Pancreas Adenocarcinoma (MSI-H) · Fondazione Policlinico Universitario Agostino Gemelli IRCCS | Not applicable | Not yet recruiting | Oct 20, 2026 |
| Immunonutrition vs EPA-DHA Enriched Nutritional Support in Patients With Cancer Undergoing SurgeryNutrition Aspect of Cancer · Maimónides Biomedical Research Institute of Córdoba | — | Recruiting | Oct 6, 2026 |
| Approved | Application | Sponsor | Supplements | Marketing |
|---|---|---|---|---|
| Feb 28, 1973 | R-Gene 10NDA 16931 · New formulation or manufacturer | Pharmacia And Upjohn | 16 | Marketed |
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Drugs@FDA
